BOSTON–(BUSINESS WIRE)–Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announcedBOSTON–(BUSINESS WIRE)–Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced

Charles River Associates (CRA) Strengthens Antitrust Practice with Addition of Former DOJ Division Leader

BOSTON–(BUSINESS WIRE)–Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that Margaret (Peggy) Loudermilk has joined the firm as a Vice President in the Antitrust & Competition Economics Practice. Peggy joins CRA from the U.S. Department of Justice’s (DOJ) Antitrust Division, where she held the position of Assistant Chief of the Economic Regulatory Section.

“We are pleased to welcome Peggy to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Peggy brings more than two decades of experience in antitrust economics and regulatory analysis. Her background will be a tremendous asset to our team as we continue to strengthen our capabilities in resolving complex competition matters.”

“During her tenure at the DOJ, Peggy was instrumental in high-profile civil and criminal matters, including mergers, conduct investigations, and cartel cases,” said Margaret Sanderson, Vice President and Global Practice Leader of the Antitrust & Competition Economics Practice at CRA. “As antitrust enforcement evolves across jurisdictions, Peggy’s experience is a great asset to our clients to understand current regulatory expectations and develop effective compliance strategies.”

Dr. Loudermilk joins Dr. Nate Goldstein (former DOJ) and Dr. Alison Hole (former FTC), expanding the practice’s roster of former senior agency economists. Their combined experience spans current areas of regulatory focus in mergers and antitrust litigation, including addressing competition in digital markets, horizontal and vertical theories of harm, and multi-jurisdictional coordination between U.S. and international agencies.

Prior to serving as Assistant Chief, Dr. Loudermilk was an Economist in the DOJ’s Antitrust Division, where she performed in-depth economic analysis and developed case recommendations for senior DOJ leadership on numerous merger, criminal, and civil non-merger investigations. She also prepared expert witnesses for trial testimony.

Dr. Loudermilk has a BA in Economics from Boston University, an MA in Economics from Duke University, and a PhD in Economics from Michigan State University.

About CRA’s Antitrust & Competition Economics Practice

CRA’s competition economists provide economic analysis and testimony in competition matters around the world. Many have served in government antitrust agencies and are members of premier academic, economic, and law faculties. Their experience extends to many industries, including healthcare, energy, computer hardware/software, retailing, telecommunications, aerospace and defense, entertainment, transportation, natural resources, sports, chemicals, pharmaceuticals, financial services, and consumer products.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Dr. Margaret Loudermilk and the strengthening of CRA’s Antitrust & Competition Economics Practice, and any future business Dr. Loudermilk may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

Contacts

Media Relations
CRA International
media@crai.com
416-825-1595

Nicholas Manganaro
Sharon Merrill Advisors
crai@investorrelations.com
617-542-5300

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.